Re: a new study that one researcher called "stunning."
in response to
by
posted on
Feb 11, 2022 09:30AM
Chicagoest - RVX/Eversana are not capable of handling mfg, distribution, marketing, product liability & support for a blockbuster.
Very good points. 40,000,000 patients is large. We all get well with 30/40 SP. For BP the potential is far to great to look the other way. Hope we see a tax free tax over, allows time to liquidate.
Question to the forum, How many patients are enrolled in the C19 P2? Study called for 50/50. We know first patient was dosed end of January. Study was 28 days, correct? Do we know? With an Open Study information should be available. sidebar.